How to Run Efficient Core Labelling Review and Update Cycles How to Run Efficient Core Labelling Review and Update Cycles Context In the field of pharmaceutical regulatory affairs, labelling represents a critical component of product information governance. Regulatory affairs and compliance are central to ensuring that labelling adheres to the legal and scientific standards set forth by health authorities such as the FDA, EMA, and MHRA. The efficient management of core labelling review and update cycles is vital for maintaining compliance and ensuring accurate communication with healthcare professionals and patients. Legal and Regulatory Basis Pharmaceutical labelling is governed by numerous…

Connecting Company Core Labelling with Risk Management Plans Connecting Company Core Labelling with Risk Management Plans Context In the pharmaceutical industry, effective communication of product information is critical for ensuring patient safety and regulatory compliance. A core component of this communication is the labelling, which must align with both regulatory expectations and pharmacovigilance activities. This article provides a deep dive into the connection between Company Core Labelling (CCL) and Risk Management Plans (RMPs), shedding light on relevant regulations, guidelines, and agency expectations in the US, UK, and EU. Legal/Regulatory Basis The regulatory framework governing pharmaceutical labelling is outlined in several…

Case Studies: When Poor CCDS Management Created Global Inconsistencies Case Studies: When Poor CCDS Management Created Global Inconsistencies The discipline of Regulatory Affairs (RA) plays a crucial role in ensuring that pharmaceutical products meet the stringent requirements set forth by regulatory authorities such as the FDA in the US, EMA in the EU, and MHRA in the UK. One of the pivotal components of successful RA is the effective management of Core Data Sheets (CDS) and Company Core Labelling (CCL) to ensure compliance across different jurisdictions. This article delves into the implications of poor Core Data Sheets (CCDS) management and…

Labelling for Multi-Indication Products: Structuring Core Content Labelling for Multi-Indication Products: Structuring Core Content Context In the complex landscape of pharmaceutical regulation, labelling serves as a critical bridge between the product and its users, ensuring the safe and effective use of medications. For multi-indication products, where a single therapeutic agent is approved for multiple clinical conditions, labelling becomes even more intricate. Regulatory Affairs (RA) professionals must navigate a myriad of guidelines and requirements to create compliant and effective product information. This article delves into the key aspects of labelling for multi-indication products, addressing the expectations set forth by regulatory authorities…

Translating Global CCDS Decisions into Affiliate-Friendly Guidance Translating Global CCDS Decisions into Affiliate-Friendly Guidance Context In the realm of pharmaceutical regulation, the Core Data Sheet (CDS) serves as a foundational document that encapsulates the essential product information approved at a global level. The Core Company Labelling (CCL), which is derived from the Core Data Sheet, ensures that local affiliates have the necessary information to adapt product labelling to meet region-specific regulations while maintaining consistency across markets. The translation of global CCDS decisions into affiliate-friendly guidance is crucial for compliance with regional regulatory affairs and ensuring that all stakeholders—from Regulatory Affairs…

Auditing Your Core Labelling System for GVP and GMP Interfaces Auditing Your Core Labelling System for GVP and GMP Interfaces In the highly regulated pharmaceutical industry, ensuring compliance with labelling requirements is crucial for maintaining product integrity and patient safety. The convergence of Good Pharmacovigilance Practices (GVP) and Good Manufacturing Practices (GMP) in labelling necessitates a robust compliance framework. This article serves as a comprehensive guide for Regulatory Affairs (RA) professionals involved in auditing core labelling systems, focusing on regulatory expectations, structures, documentation, review processes, and common deficiencies. By following these guidelines, companies can enhance their product information governance and…

How to Train Affiliates on Using and Protecting the CCDS How to Train Affiliates on Using and Protecting the CCDS Regulatory Affairs Context In the context of pharmaceutical compliance, the Company Core Data Sheet (CCDS) serves as a pivotal document that outlines essential product information for a given medicinal product. It is critical for Regulatory Affairs (RA) professionals to ensure that all subsidiaries and local affiliates are adequately trained on the appropriate use and protection of the CCDS. Misuse or misinterpretation of this document can lead to serious compliance issues and regulatory deficiencies. The CCDS acts as an anchor for…

Managing Core Labelling During Mergers, Acquisitions and Divestments Managing Core Labelling During Mergers, Acquisitions and Divestments As the pharmaceutical landscape becomes increasingly dynamic due to mergers, acquisitions, and divestments, the complexities surrounding core labelling, artwork, and product information governance cannot be underestimated. Regulatory Affairs (RA) professionals must adeptly navigate the regulatory framework while ensuring compliance with various regional requirements, particularly in the US, UK, and EU. This article provides an in-depth examination of the relevant regulations, guidelines, documentation practices, and strategies necessary for managing core labelling during these corporate changes. Context The pharmaceutical sector is characterized by rigorous regulatory oversight…

KPIs That Show Whether Your Core Labelling Process Is Under Control KPIs That Show Whether Your Core Labelling Process Is Under Control In the realm of pharmaceutical development and marketing, regulatory affairs play a crucial role in ensuring that product labelling adheres to regulatory standards set forth by various authorities, such as the FDA in the United States, the EMA in the European Union, and the MHRA in the UK. Monitoring key performance indicators (KPIs) related to labelling processes is essential for maintaining compliance and ensuring that pharmaceutical companies effectively manage their core labelling, including Company Core Labelling (CCL) and…

Digital Tools and Databases to Track Core vs Local Labelling Digital Tools and Databases to Track Core vs Local Labelling The management of pharmaceutical labelling compliance is an essential function within Regulatory Affairs (RA), particularly as it relates to the accurate representation of product information across varied markets. Digital tools and databases facilitate the tracking of Core Data Sheets (CDS) and company core labelling, while also accommodating local adaptations to ensure compliance with regional regulations. This article outlines critical regulations, guidelines, and agency expectations pertinent to labelling and provides insights on integrating pharmacovigilance systems to uphold product information governance. Context…